%0 Journal Article
%T 2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson¡¯s disease and schizophrenia
%A Ashish Kumar Gupta
%A Ashok Kumar Mohanty
%A Domada Ratna Kumar
%A Gaurav Khunger Kumar
%A Gururao Hariprasad
%A Komal Rani
%A Manjari Tripathi
%A Mohd Imran Khan
%A Perumal Vanamail
%A Rakesh Kumar Chadda
%A Rishab Gupta
%A Ruchika Pokhriyal
%A Vinay Goyal
%J Archive of "Neuropsychiatric Disease and Treatment".
%D 2019
%R 10.2147/NDT.S198559
%X Parkinson¡¯s disease and schizophrenia are clinical scenarios that occur due to dopaminergic deficit and hyperactivity in the midbrain, respectively. Current pharmacological interventions for these two diseases therefore aim to restore normal dopamine levels in the midbrain. But during therapy, there is a overshooting of dopamine concentrations that result in hallucinations in Parkinson¡¯s disease patients and extra-pyramidal symptoms in schizophrenic patients. This causes a lot of inconvenience to the patents and the clinicians. There are no tests currently available to monitor drug efficacy in these two neuropsychiatric diseases
%K Parkinson¡¯s disease
%K schizophrenia
%K gel-based proteomics
%K biomarkers
%K dopamine
%K pharmacological efficacy
%K difference gel electrophoresis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488160/